PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $626 | -25.2% | 20,407 | -2.3% | 0.01% | -28.6% |
| Q2 2023 | $837 | -1.4% | 20,879 | +0.3% | 0.01% | 0.0% |
| Q1 2023 | $849 | -1.5% | 20,807 | -6.8% | 0.01% | -12.5% |
| Q4 2022 | $862 | -99.9% | 22,314 | -0.2% | 0.01% | -27.3% |
| Q3 2022 | $1,190,000 | -6.3% | 22,367 | +2.7% | 0.01% | -8.3% |
| Q2 2022 | $1,270,000 | -24.0% | 21,785 | -0.5% | 0.01% | -7.7% |
| Q1 2022 | $1,671,000 | -39.5% | 21,890 | -52.3% | 0.01% | +30.0% |
| Q4 2021 | $2,764,000 | +112.3% | 45,930 | +97.5% | 0.01% | -9.1% |
| Q3 2021 | $1,302,000 | -8.7% | 23,252 | -1.0% | 0.01% | 0.0% |
| Q2 2021 | $1,426,000 | +215.5% | 23,498 | +264.4% | 0.01% | -35.3% |
| Q1 2021 | $452,000 | +7.4% | 6,448 | -8.4% | 0.02% | +6.2% |
| Q4 2020 | $421,000 | +2.2% | 7,037 | +2.6% | 0.02% | -11.1% |
| Q3 2020 | $412,000 | +12.6% | 6,861 | -1.8% | 0.02% | +5.9% |
| Q2 2020 | $366,000 | +42.4% | 6,984 | -9.0% | 0.02% | +183.3% |
| Q1 2020 | $257,000 | -28.4% | 7,671 | -3.1% | 0.01% | -14.3% |
| Q4 2019 | $359,000 | +31.0% | 7,919 | +10.0% | 0.01% | +16.7% |
| Q3 2019 | $274,000 | -13.6% | 7,198 | -1.4% | 0.01% | -14.3% |
| Q2 2019 | $317,000 | +37.2% | 7,299 | +20.1% | 0.01% | +16.7% |
| Q1 2019 | $231,000 | -8.0% | 6,079 | +4.1% | 0.01% | -14.3% |
| Q4 2018 | $251,000 | +2.9% | 5,837 | +9.3% | 0.01% | 0.0% |
| Q4 2017 | $244,000 | +1.7% | 5,340 | +6.2% | 0.01% | -12.5% |
| Q2 2017 | $240,000 | +17.6% | 5,030 | +12.7% | 0.01% | -20.0% |
| Q1 2017 | $204,000 | +0.5% | 4,464 | +16.4% | 0.01% | -50.0% |
| Q1 2016 | $203,000 | -24.5% | 3,836 | +9.5% | 0.02% | -39.4% |
| Q4 2015 | $269,000 | +0.7% | 3,504 | -7.1% | 0.03% | +26.9% |
| Q2 2015 | $267,000 | -17.1% | 3,770 | +4.1% | 0.03% | -33.3% |
| Q1 2015 | $322,000 | +4.2% | 3,622 | +4.0% | 0.04% | -18.8% |
| Q4 2014 | $309,000 | -8.3% | 3,482 | +0.1% | 0.05% | -4.0% |
| Q3 2014 | $337,000 | +5.3% | 3,478 | -0.0% | 0.05% | +4.2% |
| Q2 2014 | $320,000 | – | 3,479 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |